Medison Pharma Revenue and Competitors

Petach Tikva,

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Medison Pharma's estimated annual revenue is currently $125.2M per year.(i)
  • Medison Pharma's estimated revenue per employee is $201,000

Employee Data

  • Medison Pharma has 623 Employees.(i)
  • Medison Pharma grew their employee count by 8% last year.

Medison Pharma's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$46.2M2305%N/AN/A
#2
$43.8M21821%N/AN/A
#3
$57.1M28426%N/AN/A
#4
$24.5M1223%N/AN/A
#5
$52.9M26313%N/AN/A
#6
$24.7M12313%N/AN/A
#7
$1.8M180%$114.3MN/A
#8
$7.2M36-20%N/AN/A
#9
$13.7M68-7%N/AN/A
#10
$7.6M39-13%$123.9MN/A
Add Company

What Is Medison Pharma?

Medison is one of the world's largest commercial partners of leading global biotech companies. Medison is uniquely qualified to provide the complete spectrum of integrated services for biotech companies looking to enter or expand their presence in Israel, Canada, and Central East Europe. Medison runs a corporate venture arm with a dedicated research and evaluation team boasting deep scientific and commercial backgrounds. Medison also operates a scouting program to cater to its partners and is an active investor in life science projects around drug development and digital health.

keywords:N/A

N/A

Total Funding

623

Number of Employees

$125.2M

Revenue (est)

8%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Medison Pharma News

2022-04-19 - Hansa Biopharma AB's (HNSBF) CEO Søren Tulstrup on Q1 2022 Results - Earnings Call Transcript

At the end of March, Hansa and Medison Pharma announced that a marketing authorization was granted in Israel for Idefirix for...

2022-04-17 - Hansa Biopharma interim report January - March 2022

Hansa and Medison Pharma announced that a marketing authorization in Israel for Idefirix® has been granted for desensitization treatment of...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$125.2M6238%N/A
#2
$446.4M981-1%N/A
#3
$743.9M19686%N/A